GlassScriptPhysician profile
Michael A Middleton
NPI 1922087295
$1,291.35
in general payments reported to CMS, 2019-2025
22 companies · $221 in 2025
The $221 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $129 · 2021: $200 · 2022: $155 · 2023: $151 · 2024: $162 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $385.13 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $115.00 | 2019 | |
| Pfizer INC. | $103.50 | 2021-2023 | |
| Glaxosmithkline, LLC. | $93.14 | 2019-2025 | Penmenvy, Bexsero |
| Cranial Technologies, INC | $71.34 | 2019-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $70.91 | 2020-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Corium, LLC | $50.57 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $49.46 | 2021-2024 | Qelbree |
| Abbott Laboratories | $40.93 | 2025 | Id Now Instrument |
| Collegium Pharmaceutical, INC. | $39.08 | 2025 | Jornay Pm |
| Kaleo, INC. | $35.97 | 2019-2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $31.24 | 2024 | Flumist Quadrivalent |
| Abbvie INC. | $29.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.85 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $23.35 | 2022 | |
| Seqirus USA INC | $19.19 | 2024 | Flucelvax |
| Genentech USA, INC. | $18.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.04 | 2019 | |
| Phadia US INC. | $17.56 | 2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2021 | |
| Mylan Pharmaceuticals INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.